Patients with chronic lymphocytic leukemia and complex karyotype show an adverse outcome even in absence of TP53/ATM FISH deletions

• DOI: 10.18632/oncotarget.17350
• Publication Date: 2017-04-21T21:31:24Z
• Authors: Anna Puiggros; Rosa Collado; Maria José Calasanz; Margarita Ortega; Neus Ruiz-Xivillé; Alfredo Rivas-Del...; Elisa Luño; Teresa González; Blanca Navarro; MaDolores García-...; Alberto Valiente; José Ángel Hernández; María Teresa Ardanaz; María Ángeles Piñan; María Laura Blanco; María Hernández-S...; Ana Batlle-López; Rocío Salgado; Marta Salido; Ana Ferrer; Pau Abrisqueta; Eva Gimeno; Eugènia Abella; Christelle Ferrá; María José Terol; Francisco Ortuño; Dolors Costa; Carol Moreno; Félix Carbonell; Francesc Bosch; Julio Delgado; Blanca Espinet
• Keywords: Leucèmia limfoblàstica -- Aspectes genètics; complex karyotype; 03 medical and health sciences; 0302 clinical medicine; Complex karyotype; ATM deletion; Cariotips; CLL; TP53 deletion; Research Paper

// Anna Puiggros 1, 2 , Rosa Collado 3 Maria José Calasanz 4 Margarita Ortega 5 Neus Ruiz-Xivillé 6 Alfredo Rivas-Delgado 7 Elisa Luño 8 Teresa González 9 Blanca Navarro 10 MaDolores García-Malo 11 Alberto Valiente 12 Ángel Hernández 13 María Ardanaz 14 Ángeles Piñan 15 Laura Blanco 16 Hernández-Sánchez 17 Ana Batlle-López 18 Rocío Salgado 19 Marta Salido Ferrer Pau Abrisqueta Eva Gimeno 1 Eugènia Abella Christelle Ferrá Terol Francisco Ortuño Dolors Costa Carol Moreno Félix Carbonell Francesc Bosch Julio Delgado and Espinet Laboratori de Citogenètica Molecular, Citologia Hematològica, Servei Patologia i Hematologia, Hospital del Mar, Barcelona, Spain Grup Recerca Translacional en Neoplàsies Hematològiques, Programa Càncer, Institut Mar d’Investigacions Mèdiques (IMIM), Servicio Hematología, Consorcio General Universitario, Valencia, Citogenética, Departamento Genética, Universidad Navarra, Pamplona, Laboratorio Citogenética y Vall d'Hebron, ICO-Hospital Germans Trias Pujol, Contra la Leucèmia Josep Carreras (IJC), Universitat Autònoma Badalona, Secció d’Hematopatologia, Clínic, Biomèdiques Augustí Pi Sunyer (IDIBAPS), Universitario Central Asturias, Oviedo, Fundación Pública Galega Medicina Xenómica, Santiago Compostela, Hematología Oncología Médica, Clínico Morales Meseguer, Centro Regional Hemodonación, IMIB-Arrixaca, Murcia, Servicios Genética Complejo Hospitalario Infanta Leonor, Madrid, Txagorritxu, Vitoria, Cruces, Bilbao, d’Hematologia Universitari Santa Creu Sant Pau, Salamanca, IBSAL, IBMCC, Investigación Cáncer, CSIC, Marqués Valdecilla, Santander, Jiménez Díaz, Correspondence to: Espinet, email: [e-mail] Keywords: CLL, complex karyotype, ATM deletion, TP53 deletion Received: March 03, 2017      Accepted: April 11, Published: 21, 2017 ABSTRACT Genomic complexity identified by chromosome banding analysis (CBA) predicts a worse clinical outcome in CLL patients treated either with standard or new treatments. Herein, we analyzed the impact of karyotypes (CK) without high-risk FISH deletions ( and/or HR-FISH) cohort 1045 untreated MBL/CLL patients. In all, 99/1045 (9.5%) displayed CK. Despite were more common CK (25% vs 7%; P < 0.001; 40% 5%; 0.001, respectively), only 44% (40/90) showed group significant higher two-year cumulative incidence treatment (48% 20%; 0.001), as well shorter overall survival (OS) (79 mo not reached; 0.001). When categorized regarding HR-FISH, those both characteristics worst median OS (52 mo) being clearly distinct from non-CK non-HR-FISH (median reached), but no differences detected between cases HR-FISH. Both remained statistically multivariate for OS. conclusion, is globally associated advanced disease poor prognostic markers. Further investigation larger cohorts lacking HR-FISH needed to elucidate which mechanisms underlie this subgroup.